Aug. 11 at 10:23 PM
$ABSI direct quote from the call: "As you saw in June, we announced that Eli Lilly made a
$40 million strategic investment in Absci. Our partnership with Eli Lilly is tailored around the clinical development strategy for ABS-201. As a part of this collaboration, we are happy to be welcoming a representative from Lilly onto our Endometriosis Advisory Board. Zach will provide more details of this partnership later in the call. In addition to Lilly, we've seen elevated interest from the investment community in prolactin biology."
If phase 2 endometriosis data in H2 2027 look good, I can imagine that Absci will partner with Lilly for endometriosis indication only. That way, Lilly will finance the phase 3 trial and do the heavy lifting in negotiations with insurance companies etc, while Absci can use the funds for pattern hair loss and the associated phase 3 and commercialization. Huge opportunity and great outlook!
